Mozambique votes for president and the ruling party could extend its 49 years in power
Supreme Court takes up death row case with a rare alliance. Oklahoma inmate has state's support
House Democrats in close races try to show they hear voter concerns about immigration
Most Taiwanese believe China unlikely to invade in coming five years, poll shows
UK Foreign Secretary Lammy to visit Bahrain and Jordan, seeking support for regional de-escalation
Boeing halts talks, withdraws pay offer to striking union
‘I am not Satoshi Nakamoto’: Subject of HBO documentary denies he invented bitcoin
Boeing weighs options for raising cash as ratings downgrade looms, sources say
Tatis homers again as the Padres beat the Dodgers 6-5 for a 2-1 NLDS lead
Lynx return to finals with 88-77 win over Sun in Game 5 behind Collier's 27 points, 11 rebounds
Phillies one loss from elimination after 7-2 NL Division Series loss to Mets
COPENHAGEN (Reuters) - Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker said on Monday.
"This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities," Novo said in a statement.
The acquisition is expected to close before the end of this year, Novo said, adding that the deal will not impact its operating profit outlook for 2023.
Ocedurenone is an orally administered drug that is currently examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease, Novo said.
(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)
